Evidence map›Paper›PMID 35625521›Full record

ArticleBiology2022

Presence of Protease Inhibitor 9 and Granzyme B in Healthy and Pathological Human Corneas.

Stanislava Reinstein Merjava, Jan Kossl, Ales Neuwirth, Pavlina Skalicka, Zuzana Hlinomazova, Vladimir Holan, Katerina Jirsova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. A Pilot Study to Evaluate Genipin inInternational journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Stanislava Reinstein MerjavaLaboratory of the Biology and Pathology of the Eye, Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic.
Jan KosslDepartment of Nanotoxicology and Molecular Epidemiology, Institute of Experimental Medicine of the Czech Academy of Sciences, 142 20 Prague, Czech Republic.
Ales NeuwirthLaboratory of Adaptive Immunity, Institute of Molecular Genetics of the Czech Academy of Sciences, 142 20 Prague, Czech Republic.
Pavlina SkalickaDepartment of Ophthalmology, General University Hospital in Prague and First Faculty of Medicine, Charles University, 128 08 Prague, Czech Republic.
Zuzana HlinomazovaEye Clinic Lexum, 140 00 Prague, Czech Republic.
Vladimir HolanDepartment of Nanotoxicology and Molecular Epidemiology, Institute of Experimental Medicine of the Czech Academy of Sciences, 142 20 Prague, Czech Republic.
Katerina JirsovaLaboratory of the Biology and Pathology of the Eye, Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic.ORCID 0000-0002-4625-6701
Charles University · CZCzech Academy of Sciences, Institute of Experimental Medicine · CZCzech Academy of Sciences, Institute of Molecular Genetics · CZ

Funding

Charles University, Prague, Cooperatio: Medical Diagnostics and Basic Medical Sciences 001Ministry of Education, Youth and Sports of the Czech Republic BBMRI_CZ LM 2018125Norwegian Financial Mechanism 2009-2014 and the Ministry of Education, Youth and Sports of the Czech Republic MSMT-28477/2014,7F14156
6 · The paper itself

Abstract

The aim of this study was to find out whether protease inhibitor 9 (

Indexed as

corneacorneal endotheliumcorneal epitheliumgranzyme Bprotease inhibitor 9

Identifiers

PMID35625521
PMCPMC9138262
OpenAlexW4281391231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.